Navigation Links
Takeda Completes Acquisition and Names New CEO of Nycomed
Date:9/30/2011

OSAKA, Japan, September 30, 2011 /PRNewswire/ --

 

Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced it has completed its acquisition of Nycomed A/S ("Nycomed") for 9.6 billion Euro on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. Dr. Frank Morich has been named CEO of Nycomed in addition to his current role as Executive Vice President (EVP), International Operations (Americas/Europe), Takeda Pharmaceuticals International, Inc., a wholly owned subsidiary of Takeda America Holdings, Inc.

The transaction fits in with Takeda's sustainable growth strategy outlined in its 2011-2013 Mid-Range Plan (MRP). Takeda has a strong presence in the Japanese and U.S. markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialization capability. In addition, the acquisition will bring Takeda an immediate and stable increase in cash flow generated from annual revenue of more than 2.8 billion Euro from the acquired business.

"The combination of both organizations will strengthen Takeda's performance during the 2011-2013 MRP period, and enable us to sustain medium and long-term growth targets starting in fiscal 2015 and extending into the next decade," said Yasuchika Hasegawa, President & CEO of Takeda. "Partnering the two organizations will have complementary effects and further increase our potential to become a truly global pharmaceutical company."

"I look forward to bringing Takeda and Nycomed together to ensure we can achieve enhanced revenue, growth and diversification, while maintaining the strong momentum of both companies," said Frank Morich. "The combined company significantly broadens our coverage of the global pharmaceutical market to more than 70 countries, increasing our global Rx sales ranking to 12th and further strengthenin
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS , Dec. 23, 2014  Lockton ... operation of Lockton Companies, announced the addition of ... Foerster will join Lockton Dunning,s Pharmacy Consulting team, ... years of relevant industry experience to the position.  ... Managed Market Sales at Diplomat Specialty Pharmacy, where ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... BRUNSWICK, N.J., March 19, 2012  Johnson & Johnson ... and other interested parties on Monday, March 26th ... with the American College of Cardiology (ACC) Annual ... Phase 3 results of the EINSTEIN-PE study in ...
... N.J. and SYDNEY, March 19, 2012 QRxPharma Limited (ASX: ... and Option Agreement (LOA) with Actavis, Inc. which finalised the ... US acute pain marketplace.  The LOA completion follows a 20 ... secured by a US$6 million non-refundable upfront signing fee to ...
Cached Medicine Technology:QRxPharma Signs License and Option Agreement with Actavis 2QRxPharma Signs License and Option Agreement with Actavis 3QRxPharma Signs License and Option Agreement with Actavis 4
(Date:12/26/2014)... 2014 Pentec Health, Inc. number fourteen ... of Pennsylvania for 2014. The awards program, created in ... its kind in the country. The program is a ... of Community and Economic Development, the Pennsylvania State Council ... Central Penn Business Journal. , Charlie Wilson, ...
(Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3
... heart drugs may help counter the effect, researchers say ... to hasten the progression of aggressive or advanced melanoma ... slow the disease and improve the quality of patients, ... In laboratory tests, the researchers exposed samples of three ...
... There are approximately 7.1 million injury-related emergency department (ED) ... States annually, according to the Centers for Disease Control ... universities, including the University of Missouri, found that young ... to have been reported to Child Protective Services (CPS) ...
... Total Revenue Increased 15%; Online Ad Revenue Increased ... Monthly Users and 1.3 Billion Quarterly Page ViewsNEW ... WBMD ) today announced financial results ... fourth quarter results confirm WebMD,s market leadership in ...
... HLTH Corporation (Nasdaq: HLTH ... ended December 31, 2008. "We are pleased with ... Wygod, Chairman and Acting Chief Executive Officer of HLTH ... offer which reduced its shares outstanding by 45% and ...
... TELK ) announced that its year-end conference call ... 4:30 p.m. Eastern time (1:30 p.m.,Pacific time) following the release ... quarter and year ended December 31, 2008. , ... website at, http://www.telik.com or by telephone at 800-288-8974 or ...
... greatest risk seem to know the least, survey finds, , , THURSDAY, ... five warning signs of a stroke and what to do if ... according to new research. , Older people and those who,ve already ... able to recognize the symptoms of a stroke and know to ...
Cached Medicine News:Health News:Stress May Speed Melanoma Progression 2Health News:Researchers recommend increased physician awareness to reduce injuries and neglect in children 2Health News:WebMD Announces Fourth Quarter Financial Results 2Health News:WebMD Announces Fourth Quarter Financial Results 3Health News:WebMD Announces Fourth Quarter Financial Results 4Health News:WebMD Announces Fourth Quarter Financial Results 5Health News:WebMD Announces Fourth Quarter Financial Results 6Health News:WebMD Announces Fourth Quarter Financial Results 7Health News:WebMD Announces Fourth Quarter Financial Results 8Health News:WebMD Announces Fourth Quarter Financial Results 9Health News:WebMD Announces Fourth Quarter Financial Results 10Health News:WebMD Announces Fourth Quarter Financial Results 11Health News:WebMD Announces Fourth Quarter Financial Results 12Health News:WebMD Announces Fourth Quarter Financial Results 13Health News:WebMD Announces Fourth Quarter Financial Results 14Health News:WebMD Announces Fourth Quarter Financial Results 15Health News:WebMD Announces Fourth Quarter Financial Results 16Health News:WebMD Announces Fourth Quarter Financial Results 17Health News:WebMD Announces Fourth Quarter Financial Results 18Health News:WebMD Announces Fourth Quarter Financial Results 19Health News:HLTH Corporation Announces Fourth Quarter Financial Results 2Health News:HLTH Corporation Announces Fourth Quarter Financial Results 3Health News:HLTH Corporation Announces Fourth Quarter Financial Results 4Health News:HLTH Corporation Announces Fourth Quarter Financial Results 5Health News:HLTH Corporation Announces Fourth Quarter Financial Results 6Health News:HLTH Corporation Announces Fourth Quarter Financial Results 7Health News:HLTH Corporation Announces Fourth Quarter Financial Results 8Health News:HLTH Corporation Announces Fourth Quarter Financial Results 9Health News:HLTH Corporation Announces Fourth Quarter Financial Results 10Health News:HLTH Corporation Announces Fourth Quarter Financial Results 11Health News:HLTH Corporation Announces Fourth Quarter Financial Results 12Health News:HLTH Corporation Announces Fourth Quarter Financial Results 13Health News:HLTH Corporation Announces Fourth Quarter Financial Results 14Health News:HLTH Corporation Announces Fourth Quarter Financial Results 15Health News:HLTH Corporation Announces Fourth Quarter Financial Results 16
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... BioControl multichannel has the ... the single channel model.The ... allseven multichannel and five ... modules. Both pipettes have ...
Medicine Products: